nivolumab,ipilimumab
bms
['niche-2']
#esmo22 highlights: neoadjuvant immune checkpoint inhibition in locally advanced mmr-deficient #coloncancer: the niche-2 study 
The European Society for Medical Oncology (ESMO) is the leading organisation for cancer education and information, supporting the oncology community’s work.